The goals of the core are to provide all projects with centralized leadership and administrative support, and to ensure effective communication among all projects and cores so that translational objectives are being met. To achieve this goal the core will arrange internal group meetings including the monthly investigator meeting, executive committee meetings and invited research lectures. It will oversee the overall fiscal and budgetary management of the SPORE and provide assistance to each project and core leader, with a particular focus on assisting budgetary planning for clinical translation. The Core will also use its discretionary funds to support new research opportunities or unexpected costs. During the initial funding period, this core has monitored each project with input from the Executive Committee and Advisory Board, and modified projects and incorporated new directions as necessary. For the current proposal. Administrative Core leaders will ensure continued SPORE oversight by convening meetings of the Internal and Advisory Boards and assessing and implementing their recommendations. The activities of the Career Development and the Developmental Research Programs will both be co-ordinated with other SPORE activities through this Administrative Core to ensure that the objectives of these programs are being met. Finally the Administrative Core will communicate with the NCI SPORE program Staff and encourage and facilitate collaboration with other SPORES and networks.
The Administrative Core supports the leadership of all SPORE projects and cores and integrates these with the Career Development and Developmental Research Programs. It organizes meetings to monitor progress and promote collaboration and identifies new research opportunities.
|Rouce, Rayne H; Heslop, Helen E (2016) Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov 6:579-80|
|Yang, Liubin; Rodriguez, Benjamin; Mayle, Allison et al. (2016) DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 29:922-34|
|Bollard, Catherine M; Heslop, Helen E (2016) T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127:3331-40|
|Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2016) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol :|
|Ramos, Carlos A; Heslop, Helen E; Brenner, Malcolm K (2016) CAR-T Cell Therapy for Lymphoma. Annu Rev Med 67:165-83|
|Ramos, Carlos A; Savoldo, Barbara; Torrano, Vicky et al. (2016) Clinical responses with T lymphocytes targeting malignancy-associated Îº light chains. J Clin Invest 126:2588-96|
|Rau, Rachel E; Rodriguez, Benjamin A; Luo, Min et al. (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128:971-81|
|Zhou, Xiaoou; Naik, Swati; Dakhova, Olga et al. (2016) Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther 24:823-31|
|Eckstein, Olive S; Wang, Linghua; Punia, Jyotinder N et al. (2016) Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol 44:740-4|
|Naik, Swati; Nicholas, Sarah K; Martinez, Caridad A et al. (2016) Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 137:1498-1505.e1|
Showing the most recent 10 out of 218 publications